Market outlook of the global hemophilia B market
Hemophilia B, commonly known as Christmas disease, is a genetic blood coagulation disorder that is caused due to factor IX deficiency. Even though this is an inherited disease, approximately one-third of the cases occur due to spontaneous gene mutation. Analysts estimate the market for hemophilia B to surpass US$ 2 billion due to the advent of plasma-derived and recombinant factor replacement therapeutics.
Technavio’s market research analysts estimate the Americas to account for approximately 44% of the total market revenue during the forecast period. This region’s domination of the market can be attributed to the increase in prophylactic treatment and development of long-acting hemophilia B therapeutic products.
Competitive landscape and key vendors
The launch of long-acting drugs for factor replacement therapies and its acceptance among the end users is expected to drive market growth by augmenting the revenues generated by companies. Competitiveness in this market is expected to deepen with an increase in strategic alliances and technological advancements.
Leading vendors in this market are –
- Baxter
- Grifols
- Novo Nordisk
- Pfizer
Other prominent vendors in this market are Alnylam Pharmaceuticals, Amarna Therapeutics, Asklepios, Biogen, Catalyst Biosciences, CSL Behring, Dimension Therapeutics, Dong-A Socio, Emergent BioSolutions, Kedrion, OPKO Health, rEVO Biologics, Sangamo BioSciences, Spark Therapeutics, Swedish Orphan Biovitrum, and uniQure.
Segmentation by disease severity and analysis of the hemophilia B market
- Mild hemophilia B
- Moderate hemophilia B
- Severe hemophilia B
The moderate hemophilia B segment accounts for approximately 37% of the total market size and is expected to dominate over the other two segments during the forecast period. In moderate hemophilia B, the activity of factor IX is in the range of 1 to 5% and maybe associated with bleeding episodes after injuries.
Disease-management segmentation of the hemophilia B market
- On-demand therapy
- Prophylaxis
- Inhibitors
In this market research report, analysts estimate the on-demand therapy segment to account for more than 80% of the total market share. The on-demand therapy is widely popular in developing economies like APAC and EMEA, where access to proper healthcare facilities is limited. Also, low awareness pertaining to disease prophylaxis is another factor that is expected to promote the implementation of on-demand treatments in these regions.
Key questions answered in the report include
- What will the market size and the growth rate be in 2019?
- What are the key factors driving the global hemophilia B market?
- What are the key market trends impacting the growth of the global hemophilia B market?
- What are the challenges to market growth?
- Who are the key vendors in the global hemophilia B market?
- What are the market opportunities and threats faced by the vendors in the global hemophilia B market?
- Trending factors influencing the market shares of the EMEA, Americas, and APAC?
- What are the key outcomes of the five forces analysis of the global hemophilia B market?
Technavio also offers customization on reports based on specific client requirement.
Related reports
Global Hemophilia Market 2014-2018
Global Healthcare IT Spending - Market Analysis 2015-2019
Global Preimplantation Genetic Diagnosis (PGD) Market 2014-2018
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
- Market overview
- Top-vendor offerings
PART 03: Market research methodology
- Research methodology
- Economic indicators
PART 04: Introduction
PART 05: Market landscape
- Market overview
- Market size and forecast
- Five forces analysis
PART 06: Disease overview
- Understanding the disease
- Epidemiology
PART 07: Pipeline portfolio
- Key information of few pipeline candidates
PART 08: Market segmentation by disease severity
- Mild hemophilia B
- Moderate hemophilia B
- Severe hemophilia B
PART 09: Market segmentation by disease management
- On-demand therapy
- Prophylactic therapy
- Inhibitor therapy
PART 10: Geographical segmentation
PART 11: Market drivers
- Focus on prophylactic treatment
- Drugs with prolonged action
- Patient assistance programs
PART 12: Impact of drivers
PART 13: Market challenges
- High cost of therapy
- Low diagnosis rate in developing countries
- Complications of available therapies
PART 14: Impact of drivers and challenges
PART 15: Market trends
- Advances in technology
- Strategic alliances
- Development of gene therapy products
PART 16: Vendor landscape
- Competitive scenario
- Mergers and acquisitions
- Market share analysis 2014
- Other prominent vendors
PART 17: Key vendor analysis
- Baxter
- Grifols
- Novo Nordisk
- Pfizer
PART 18: Explore Technavio